Synthesis and antimicrobial studies on novel sulfonamides containing 4-azidomethyl coumarin by Basanagouda, M. et al.
lable at ScienceDirect
European Journal of Medicinal Chemistry 45 (2010) 1151–1157Contents lists avaiEuropean Journal of Medicinal Chemistry
journal homepage: ht tp: / /www.elsevier .com/locate /e jmechOriginal article
Synthesis and antimicrobial studies on novel sulfonamides containing
4-azidomethyl coumarin
Mahantesha Basanagouda a, K. Shivashankar b, Manohar V. Kulkarni a,*, Vijaykumar P. Rasal c,
Harishchandra Patel c, Sumit S. Mutha c, Ashwini A. Mohite c
a P.G. Department of Chemistry, Karnatak University, Dharwad 580 003, Karnataka, India
b P.G. Department of Chemistry, Central College, Bangalore University, Bangalore 560 001, Karnataka, India
cDepartment of Pharmacology, KLES’s College of Pharmacy, Belgaum-590 010, Karnataka, Indiaa r t i c l e i n f o
Article history:
Received 5 January 2009
Received in revised form
9 October 2009
Accepted 10 December 2009
Available online 21 December 2009
Keywords:
Coumarin
Sulfonamide
Azide
Antimicrobial activity* Corresponding author. Tel.: þ91 836 2215286; fax
E-mail address: manohar274@gmail.com (M.V. Ku
0223-5234/$ – see front matter  2009 Elsevier Mas
doi:10.1016/j.ejmech.2009.12.022a b s t r a c t
A series of new and novel coumarin-6-sulfonamides with a free C4-azidomethyl group have been
synthesized as antimicrobials in three steps starting from 7-methyl-4-bromomethylcoumarin 1. The
reaction of 1 with chlorosulfonic acid was found to yield the corresponding 6-sulfonylchloride 2, which
when treated with sodium azide led to intermediate 3. The title sulfonamides 5a–y were obtained from
the reaction of 3 with various aromatic amines 4 in reﬂuxing benzene. The chemical structures of the
compounds were elucidated by IR, NMR and LC-MS spectral data. All the synthesized compounds have
been screened for their in vitro anti-bacterial and anti-fungal activities. Some of the compounds have
been found to be active against both bacterial species at a concentration of 1 mg/mL.
 2009 Elsevier Masson SAS. All rights reserved.1. Introduction
Coumarins are a class of lactoneswhich are foundwidely innature
and possess antiinﬂammatory [1,2], antiviral [3], antiHIV [4], anti-
fungal [5] and cytotoxic activities [6,7], which have been reviewed
[8]. In the development of newer antimicrobials, coumarins have
been identiﬁed as target speciﬁc plant anti-bacterial agents with
growth inhibitory potential particularly against Gram-positive
species [9]. This is based on the related antibiotic novobiocin which
targets the DNA gyrase [10]. Synthetic coumarins with chloram-
phenicol [11] side chain and cephalosporin amides [12] at C-3 posi-
tion, have been screened against a number of bacterial species. One of
the earliest attempts to enhance their antimicrobial potency led to 6-
sulphonamido coumarins [13–16], as anti-tubercular agents. Intro-
duction of a basic side chain at the allylic positionwith respect to the
biogenetically important C3-C4 double bond [17] was attempted to
reduce the acidic character of coumarin antibiotics. Amongst the
various alkyl amines and sulﬁdes synthesized, the 4-piper-
azinomethyl and imidazomethyl sulﬁdes [18] were found to be the
most active compounds. We have been studying structurally analo-
gous, 4-arylaminomethyl [19] 4-sulphonamidomethyl [20] and 4-: þ 91 836 2747884.
lkarni).
son SAS. All rights reserved.dichloroacetamidomethyl coumarins [21] for their anti-bacterial
activity. Recent reports on the cytotoxic effects of coumarin sulfon-
amides [22,23], on leukemia cell lines have generated a renewed
interest in such class of compounds. Azido grouphas been recognized
as a bioorthogonal chemical reporter which is stable in physiological
conditions [24] and has been employed in the study of biosynthetic
pathways of biomolecules [25,26]. It is also expected that the polar
nature of the azide would play an important role in penetrating the
cell wall thus enhancing the bacterial potency of the compounds. In
continuation of our interest in designing oxygen heterocycle based
anti-bacterials [27], we have synthesized new sulfonamides with an
azido group at the allylic position in the coumarin ring and the results
of anti-bacterial and anti-fungal activity have been discussed in this
paper.
2. Chemistry
4-Bromoethylacetoacetate obtained from the bromination of
ethylacetoacetate, was treated with m-cresol under Pechmann
cyclization conditions using neat sulphuric acid as the condensing
agent. The reaction resulted in the formation of 4-bromomethyl-
7-methylcoumarin 1. The reactivity of this compound has been
explored in a cascaded manner via a regioselective electrophilic
substitution, allylic SN reaction and a nucleophilic displacement at
the oxidized sulfur. Compound 1 was reﬂuxed with excess of
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sulfonylchloride 2. The regioselective electrophilic substitution at
C-6 is probably because of the electron donating C7-CH3 group
and the spatial proximity of C-6 with the ring oxygen, which
resembles the para-position of phenols.
Treatment 2 with sodium azide in aqueous acetone at room
temperature resulted in the formation of 4-azidomethyl-7-meth-
ylcoumarin-6-sulfonyl chloride 3, the structure of which was sup-
ported by spectral data. Preferential attack of the linear azide
nucleophile at the allylic carbon is favorably due to the better
leaving group ability of bromine and slight steric hindrance caused
by the ortho-methyl group at C-7. However use of two equivalents
of sodium azide at room temperature leads to the formation of bis-
azide expected because of the higher reactivity of sulfonyl chloride
which has been recently reported in the reactions of 4-bromo-
methyl-benzenesulfonyl chloride [28]. Sulfonamides 5a–y were
obtained by reﬂuxing aromatic amines and sulfonyl chloride
derivative 3 in dry benzene. Removal of solvent under reduced
pressure afforded the title compounds as solids which were puri-
ﬁed by routine methods (Scheme 1).Br
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Scheme 1. Synthesis of 4-azidomethyl-73. Results and discussion
Structure of C-6 sulfonyl chloride 2 was supported by the
appearance of two singlets in the 1H NMR at 7.40 and 8.45 ppm due
to C5-H and C8-H respectively. The C4-CH2 protons appeared as
singlet at 4.52 ppmwhere as C3-H observed as singlet at 6.63 ppm.
Formation of azide 3was indicated by a strong band at 2135 cm1. It
was the change in the chemical shift of methylene protons to
5.00 ppm which supported the observed regiochemistry of the
nucleophilic displacement at the allylic carbon under the present
experimental conditions. Expectedly there was no signiﬁcant
change in the aromatic region with singlets appearing at 7.69 and
8.24 ppm. Generation of sulfonamides 5a-ywas indicated bya sharp
band around 3360 cm1 and the azide group remained in-tact
during the nucleophilic displacement at the sulfonyl chloride 3. In
the PMR spectrum of 4-azidomethyl-7-methyl-coumarin-6-
sulfonic acid p-tolylamide (5c) (R ¼ –C6H4–CH3-p) showed two
singlets at 2.29 and2.66 dppmdue toC7-CH3 andCH3of phenyl ring,
respectively. The NH proton was observed as singlet at 4.49 ppm.
The methylene protons linked to azido group were observed asO O
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observed as singlet at 6.47 ppm. The aromatic protons resonated in
the region of 6.55–8.30 ppm. Further evidence for the formation of
sulfonamides was obtained from the mass spectral data. The Mass
spectrum of (5c) (R ¼ –C6H4–CH3-p) shows M þ H peak atm/z 385.
4. Biological screening
4.1. Anti-bacterial screening
All the newly synthesized compounds were evaluated for their in
vitro anti-bacterial activity against (i) Gram-positive bacteria: Strep-
tococcus faecalis (MTCC 3382), Staphylococcus aureus (MTCC 3160),
Bacillus subtilis (MTCC 297) and (ii) Gram-negative bacteria: Pseudo-
monas aeruginosa (MTCC 1034), Klebsiella pneumoniae (MTCC 3384)
and Escherichia coli (MTCC 1089) by broth microdilutionmethod [29].
The anti-bacterial data (Table 1) revealed that all the sulfonamides
exhibitedmoderate activitya fewof themhighlyactive, butmajorityof
them inactive against E. coli. Compounds with methoxy group 5g, 5h,
5i, 5j, 5kwere highly active against S. faecaliswithMIC of 1 mg/mL. The
m-methoxy compound 5h was found to equally effective against P.
aeruginosa andK. pneumoniaewithMIC of 1 and 2 mg/mL, respectively.
The 2-chloro compound 5n and 4-bromo compound 5swere found to
be veryactive against S. faecalis, P. aeruginosa andK.pneumoniae.Many
compounds exhibited MIC similar to ciproﬂoxacin against three
bacterial species except E. coli. Highest activity was associated with
mono-nitro, chloro, bromo and methoxy substituents.
4.2. Anti-fungal screening
All the sulfonamides were screened for their anti-fungal activity
against Candida albicans, Aspergillus fumigatus, Aspergillus niger,
Penicillium chrysogenum, Mucor fuscus and Fusarium oxysporum in
DMSO by broth micro dilution method [30].
The screening data (Table 2) gives a spectrum of their activity
and all of them were most active against F. oxysporum . The mostTable 1
Results of anti-bacterial activities of compounds 2, 3 and 5a–y MICs (mg/mL).
Compound R Gram-positive
S. faecalis S. aureus
2 – 16 16
3 – 31.25 4
5a H 31.25 4
5b 3-CH3 250 16
5c 4-CH3 16 16
5d 3,4-CH3 8 4
5e 2,4-CH3 62.5 16
5f 2,6-CH3 >500 125
5g 2-OCH3 1 31.25
5h 3-OCH3 1 16
5i 4-OCH3 1 4
5j 4-OC2H5 1 2
5k 2-NO2 1 1
5l 3-NO2 8 4
5m 4-NO2 4 2
5n 2-Cl 1 1
5o 3-Cl 8 1
5p 4-Cl 4 8
5q 2,4-Cl 1 31.25
5r 3,4-Cl 16 4
5s 4-Br 1 16
5t 3-Cl, 4-CH3 8 8
5u 2-Cl, 5-NO2 2 2
5v 2-NO2, 4-Cl 4 4
5w 2-NO2, 4-CH3 1 16
5x 2-CH3, 4-NO2 4 16
5y Naphthylamine 2 16
Ciproﬂoxacin – 1 1active compounds against C. albicans were 5c, 5b and 5u with 4-
methyl, 3-methyl and 2-chloro-5-nitro substituents exhibiting
MICs of 1, 4 and 4 mg/mL, respectively. The 2,6-dimethyl, 4-
methoxy, 2-chloro-5-nitro and naphthyl exhibited 2 mg/mL MIC
against A. fumigatus. A broad spectrum of anti-fungal activity was
observed in 5b, 5h, 5i, 5y for A. niger. Other compounds those were
effective at 2 mg/mL against P. chrysogenum were 5a, 5d, 5l, 5o, 5r
and 5x. The compounds 5a, 5d, 5h, 5l and 5x showed signiﬁcant
activity against M. fuscus. It is interesting to note that all these
compounds exhibited a better activity than ﬂuconazole.
5. Experimental
5.1. Chemistry
The melting points were determined by open capillary method
and are uncorrected. The IR spectra (KBr disc) were recorded on
a Nicolet-5700 FT-IR spectrophotometer. 1H NMR spectra were
recorded on Bruker 300MHz spectrometer using CDCl3 and DMSO-
d6 as solvents and TMS as an internal standard. The chemical shifts
are expressed in d ppm. The mass spectra were recorded using
Agilent-single Quartz LC-MS. The elemental analysis was carried
out using Heraus CHN rapid analyzer. The purity of the compound
was checked by T.L.C. All the chemicals purchased were of analyt-
ical grade, and were used without further puriﬁcation unless
otherwise stated.
5.1.1. Synthesis of 4-bromomethyl-7-methylcoumarin (1)
The required 4-bromomethyl-7-methylcoumarin [19] have been
synthesized by the Pechmann cyclization of m-cresol with 4-bro-
moethylacetoacetate [31].
5.1.2. Synthesis of 4-bromomethyl-7-methyl-coumarin-6-sulfonyl
chloride (2)
4-Bromomethyl-7-methylcoumarin 1 (2.53 g, 0.01 mol) was
taken in a two-necked R. B. ﬂask with a dropping funnel and reﬂuxGram-negative
B. subtilis P. aeruginosa K. pneumoniae E. coli
16 125 125 125
31.25 125 125 125
31.25 125 125 125
16 2 4 >500
8 125 1 >500
31.25 125 125 125
125 4 62.5 >500
>500 2 1 >500
>500 125 62.5 250
>500 1 2 >500
>500 8 1 250
>500 62.5 16 62.5
62.5 4 16 >500
8 125 125 125
125 1 2 250
125 31.25 1 >500
16 1 4 >500
16 1 1 >500
250 2 2 >500
2 8 1 >500
>500 1 1 >500
4 1 8 >500
125 2 62.5 >500
250 8 16 >500
250 16 4 250
4 125 31.25 125
>500 8 1 >500
1 1 1 1
Table 2
Results of anti-fungal activities of compounds 2, 3 and 5a–y MICs (mg/mL).
Compound R C. albicans A. fumigatus A. niger P. chrysogenum M. fuscus F. oxysporum
2 – 8 4 4 1 1 1
3 – 8 8 8 4 2 2
5a H 16 8 8 2 4 4
5b 3-CH3 4 8 1 8 62.5 125
5c 4-CH3 1 16 4 16 62.5 1
5d 3,4-CH3 8 8 4 2 1 1
5e 2,4-CH3 8 16 4 31.25 16 1
5f 2,6-CH3 8 2 8 31.25 16 1
5g 2-OCH3 31.25 62.5 16 >500 31.25 1
5h 3-OCH3 8 31.25 2 125 4 1
5i 4-OCH3 8 2 2 250 250 1
5j 4-OC2H5 16 >500 250 >500 62.5 1
5k 2-NO2 250 8 8 4 8 1
5l 3-NO2 16 8 8 2 4 2
5m 4-NO2 62.5 250 62.5 62.5 8 1
5n 2-Cl 62.5 31.25 62.5 31.25 16 4
5o 3-Cl >500 16 31.25 2 >500 1
5p 4-Cl 8 125 31.25 16 16 1
5q 2,4-Cl 8 250 250 62.5 16 1
5r 3,4-Cl 16 31.25 16 2 31.25 1
5s 4-Br 125 500 500 16 250 1
5t 3-Cl, 4-CH3 31.25 16 16 4 16 1
5u 2-Cl, 5-NO2 4 2 8 125 62.5 1
5v 2-NO2, 4-Cl 16 500 62.5 125 8 1
5w 2-NO2, 4-CH3 16 125 31.25 31.25 62.5 1
5x 2-CH3, 4-NO2 16 8 4 2 2 2
5y Naphthylamine 8 2 1 16 31.25 1
Fluconazole – 8 8 8 8 8 8
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0.06 mol) was added through a dropping funnel in small portion
with occasional shaking. The reaction mixture was heated on
a water bath for 1 h (monitored by TLC), cooled and poured on to
crushed ice (100 g). The separated solid was ﬁltered off, washed
with water, dried and recrystallized from chloroform to obtain
a colorless solid in 55% yield. m.p. 170–171 C; IR (KBr) cm1 1716
(C]O); 1H NMR (CDCl3, 300 MHz, TMS): d 2.89 (s, 3H, C7-CH3), 4.52
(s, 2H, C4-CH2), 6.63 (s, 1H, C3-H), 7.40 (s, 1H, C8-H), 8.45 (s, 1H, C5-
H); LC-MS: 353 (M þ 2). Anal. Calcd for C11H8BrClO4S (%): Calcd. C,
37.58; H, 2.29. Found: C, 37.21; H, 2.02.
5.1.3. Synthesis of 4-azidomethyl-7-methyl-coumarin-6-sulfonyl
chloride (3)
4-Bromomethyl-7-methyl-coumarin-6-sulfonyl chloride 2
(3.51 g, 0.01 mol) was taken in acetone (20 ml) in R. B. ﬂask. To this,
solution of sodium azide (0.78 g, 0.012 mol) in water (3 ml) was
added drop wise with stirring. The stirring was continued for 10 h.
Then, the reaction mixture was poured on to crushed ice (100 g).
The separated solid was ﬁltered and recrystallized from benzene to
obtain a colorless solid in 65% yield. m.p. 120–121 C; IR (KBr) cm1
1728 (C]O), 2135 (N3, azido);
1H NMR (CDCl3, 300 MHz, TMS):
d 2.77 (s, 3H, C7-CH3), 4.66 (s, 2H, C4-CH2), 6.67 (s, 1H, C3-H), 7.39
(s, 1H, C8-H), 8.35 (s, 1H, C5-H); Anal. Calcd for C11H8ClN3O4S (%):
Calcd. C, 42.11; H, 2.57; N, 13.39. Found: C, 42.01; H, 2.31; N, 13.11.
5.1.4. Synthesis of 4-azidomethyl-7-methyl-coumarin-6-
sulfonamides (5): general procedure
To a mixture of 4-azidomethyl-7-methyl-coumarin-6-sulfonyl
chloride 3 (3.13 g, 0.01 mol) in dry benzene (30 ml) the appropriate
aromatic amines 4 (0.015 mol) were added and heated under reﬂux
for 4 h (18–20 h for nitro amines) (monitored by TLC). The solvent
was removed under reduced pressure. The residue obtained was
ﬁltered off and crystallized from benzene.
5.1.4.1. Synthesis of 4-azidomethyl-7-methyl-coumarin-6-sulfonic
acid phenylamide (5a). Colorless solid; yield 70%; m.p. 168 C; IR(KBr) cm1 1716 (C]O), 2124 (N3), 3367 (NH); 1H NMR (DMSO,
300 MHz, TMS): d 2.67 (s, 3H, C7-CH3), 5.12 (s, 2H, C4-CH2), 6.37 (s,
1H, C3-H), 6.63–8.39 (m, 8H, Ar-H and NH); Anal. Calcd for
C17H14N4O4S (%): Calcd. C, 55.13; H, 3.81; N, 15.13. Found: C, 55.02;
H, 3.57; N, 15.01.
5.1.4.2. 4-Azidomethyl-7-methyl-coumarin-6-sulfonic acid m-tolyla-
mide (5b). Yellow solid; yield 75%; m.p. 110 C; IR (KBr) cm1 1714
(C]O), 2120 (N3), 3345 (NH);
1H NMR (DMSO, 300 MHz, TMS):
d 2.66 (s, 3H, C7-CH3), 3.51 (s, 3H, 3-CH3 of phenyl), 4.59 (s, 1H, NH,
D2O exchangeable), 4.93 (s, 2H, C4-CH2), 6.34 (s, 1H, C3-H), 6.55–
8.37 (m, 6H, Ar-H); LC-MS 385 (MþH). Anal. Calcd for C18H16N4O4S
(%): Calcd. C, 56.24; H, 4.20; N, 14.57. Found: C, 56.14; H, 4.13; N,
14.40.
5.1.4.3. 4-Azidomethyl-7-methyl-coumarin-6-sulfonic acid p-tolyla-
mide (5c). Brown solid; yield 72%; m.p. 188 C; IR (KBr) cm1 1710
(C]O), 2115 (N3), 3341 (NH);
1H NMR (DMSO, 300 MHz, TMS):
d 2.29 (s, 3H, 4-CH3 of phenyl), 2.66 (s, 3H, C7-CH3), 4.49 (s, 1H, NH,
D2O exchangeable), 4.78 (s, 2H, C4-CH2), 6.47 (s, 1H, C3-H), 6.55–
8.30 (m, 6H, Ar-H); LC-MS 385 (MþH). Anal. Calcd for C18H16N4O4S
(%): Calcd. C, 56.24; H, 4.20; N, 14.57. Found: C, 56.04; H, 4.04; N,
14.39.
5.1.4.4. 4-Azidomethyl-7-methyl-coumarin-6-sulfonic acid (3,4-
dimethyl-phenyl)-amide (5d). Colorless solid; yield 70%; m.p.
190 C; IR (KBr) cm1 1712 (C]O), 2115 (N3), 3352 (NH); 1H NMR
(DMSO, 300 MHz, TMS): d 2.00 (s, 3H, 4-CH3 of phenyl), 2.66 (s, 3H,
C7-CH3), 3.90 (s, 3H, 3-CH3 of phenyl), 5.00, (s, 2H, C4-CH2), 6.60 (s,
1H, C3-H), 6.70–8.40 (m, 5H, Ar-H), 10.0 (s, 1H, NH, D2O
exchangeable). Anal. Calcd for C19H18N4O4S (%): Calcd. C, 57.27; H,
4.55; N, 14.06. Found: C, 57.03; H, 4.32; N, 13.92.
5.1.4.5. 4-Azidomethyl-7-methyl-coumarin-6-sulfonic acid (2,4-
dimethyl-phenyl)-amide (5e). Brown solid; yield 69%; m.p. 161 C;
IR (KBr) cm1 1730 (C]O), 2134 (N3), 3440 (NH); 1H NMR (DMSO,
300 MHz, TMS): d 2.13 (s, 6H, 2-CH3 and 4-CH3 of phenyl), 2.69 (s,
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5H, Ar-H), 8.51 (s, 1H, NH, D2O exchangeable). Anal. Calcd for
C19H18N4O4S (%): Calcd. C, 57.27; H, 4.55; N, 14.06. Found: C, 57.12;
H, 4.48; N, 14.01.
5.1.4.6. 4-Azidomethyl-7-methyl-coumarin-6-sulfonic acid (2,6-
dimethyl-phenyl)-amide (5f). Green solid; yield 65%; m.p. 185 C; IR
(KBr) cm1 1730 (C]O), 2134 (N3), 3440 (NH); 1H NMR (DMSO,
300 MHz, TMS): d 2.13 (s, 6H, 2-CH3 and 4-CH3 of phenyl), 2.69 (s,
3H, C7-CH3), 5.16 (s, 2H, C4-CH2), 6.35 (s, 1H, C3-H), 6.70–8.25 (m,
5H, Ar-H), 8.51 (s, 1H, NH, D2O exchangeable). Anal. Calcd for
C19H18N4O4S (%): Calcd. C, 57.27; H, 4.55; N, 14.06. Found: C, 57.12;
H, 4.48; N, 13.97.
5.1.4.7. 4-Azidomethyl-7-methyl-coumarin-6-sulfonic acid (2-
methoxy-phenyl)-amide (5g). Black solid; yield 75%; m.p. 206 C; IR
(KBr) cm1 1739(C]O), 2143 (N3), 3433 (NH); 1H NMR (DMSO,
300 MHz, TMS): d 2.68 (s, 3H, C7-CH3), 3.82 (s, 3H, 2-OCH3 of
phenyl), 4.66 (s, 2H, C4-CH2), 6.27 (s, 1H, C3-H), 6.47–8.28 (m, 6H,
Ar-H), 8.41 (s, 1H, NH, D2O exchangeable). Anal. Calcd for
C18H16N4O5S (%): Calcd. C, 53.99; H, 4.03; N, 13.99. Found: C, 53.90;
H, 3.92; N, 13.94.
5.1.4.8. 4-Azidomethyl-7-methyl-coumarin-6-sulfonic acid (3-
methoxy-phenyl)-amide (5h). Green solid; yield 77%; m.p.119 C; IR
(KBr) cm1 1725 (C]O), 2123 (N3), 3372 (NH); 1H NMR (DMSO,
300 MHz, TMS): d 2.66 (s, 3H, C7-CH3), 3.58 (s, 3H, 3-OCH3 of
phenyl), 4.55 (s, 1H, NH, D2O exchangeable), 4.93 (s, 2H, C4-CH2),
6.38 (s, 1H, C3-H), 7.65 (s, 1H, C8-H), 6.61–8.21 (m, 4H, Ar-H), 8.38
(s, 1H, C5-H); LC-MS 401 (M þ H). Anal. Calcd for C18H16N4O5S (%):
Calcd. C, 53.99; H, 4.03; N, 13.99. Found: C, 53.90; H, 3.95; N, 13.92.
5.1.4.9. 4-Azidomethyl-7-methyl-coumarin-6-sulfonic acid (4-
methoxy-phenyl)-amide (5i). Green solid; yield 74%; m.p. 200 C; IR
(KBr) cm1 1714 (C]O), 2123 (N3), 3356 (NH); 1H NMR (DMSO,
300 MHz, TMS): d 2.67 (s, 3H, C7-CH3), 3.39 (s, 3H, 4-OCH3 of
phenyl), 4.83 (s, 2H, C4-CH2), 6.58 (s, 1H, C3-H), 7.05–7.48 (m, 5H,
Ar-H), 7.57 (s, 1H, NH, D2O exchangeable), 8.14 (s, 1H, C5-H); LC-MS
401 (M þ H). Anal. Calcd for C18H16N4O5S (%): Calcd. C, 53.99; H,
4.03; N, 13.99. Found: C, 53.94; H, 3.99; N, 13.94.
5.1.4.10. 4-Azidomethyl-7-methyl-coumarin-6-sulfonic acid (4-
ethoxy-phenyl)-amide (5j). Green solid; yield 70%; m.p. 191 C; IR
(KBr) cm1 1705 (C]O), 2115 (N3), 3325 (NH); 1H NMR (DMSO,
300MHz, TMS): d 1.31 (t, 3H, CH3 of C2H5), 2.64 (s, 3H, C7-CH3), 3.46
(q, 2H, CH2 of C2H5), 4.51 (s, 2H, C4-CH2), 6.37 (s, 1H, C3-H), 6.51–
7.34 (m, 5H, Ar-H), 7.57 (s, 1H, NH, D2O exchangeable), 8.35 (s, 1H,
C5-H); Anal. Calcd for C19H18N4O5S (%): Calcd. C, 55.06; H, 4.38; N,
13.52. Found: C, 55.00; H, 4.29; N, 13.48.
5.1.4.11. 4-Azidomethyl-7-methyl-coumarin-6-sulfonic acid (2-nitro-
phenyl)-amide (5k). Yellow solid; yield 64%; m.p. 101 C; IR (KBr)
cm11725 (C]O), 2122 (N3), 3351 (NH); 1H NMR (DMSO, 300 MHz,
TMS): d 2.68 (s, 3H, C7-CH3), 4.98 (s, 2H, C4-CH2), 6.63 (s, 1H, C3-H),
6.91–8.09 (m, 5H, Ar-H), 8.24 (s, 1H, C5-H), 8.40 (s, 1H, NH, D2O
exchangeable). Anal. Calcd for C17H13N5O6S (%): Calcd. C, 49.16; H,
3.15; N, 16.86. Found: C, 49.09; H, 3.08; N, 16.73.
5.1.4.12. 4-Azidomethyl-7-methyl-coumarin-6-sulfonic acid (3-nitro-
phenyl)-amide (5l). Yellow solid; yield 62%; m.p. 101 C; IR (KBr)
cm11727 (C]O), 2099 (N3), 3344 (NH); 1H NMR (DMSO, 300MHz,
TMS): d 2.50 (s, 3H, C7-CH3), 4.80 (s, 2H, C4-CH2), 6.20 (s, 1H, C3-H),
6.30–9.17 (m, 7H, Ar-H and NH). Anal. Calcd for C17H13N5O6S
(%): Calcd. C, 49.16; H, 3.15; N, 16.86. Found: C, 49.02; H, 3.01; N,
16.81.5.1.4.13. 4-Azidomethyl-7-methyl-coumarin-6-sulfonic acid (4-nitro-
phenyl)-amide (5m). Yellow solid; yield 61%; m.p. 165 C; IR (KBr)
cm11726 (C]O), 2123 (N3), 3431 (NH); 1H NMR (DMSO, 300MHz,
TMS): d 2.68 (s, 3H, C7-CH3), 4.98 (s, 2H, C4-CH2), 6.58 (s, 1H, C3-H),
6.81–7.95 (m, 5H, Ar-H), 8.24 (s, 1H, C5-H), 8.40 (s, 1H, NH, D2O
exchangeable). Anal. Calcd for C17H13N5O6S (%): Calcd. C, 49.16; H,
3.15; N, 16.86. Found: C, 49.10; H, 3.08; N, 16.78.
5.1.4.14. 4-Azidomethyl-7-methyl-coumarin-6-sulfonic acid (2-
chloro-phenyl)-amide (5n). Brown solid; yield 65%; m.p. 184 C; IR
(KBr) cm1 1728 (C]O), 2125 (N3), 3409 (NH); 1H NMR (DMSO,
300 MHz, TMS): d 2.67 (s, 3H, C7-CH3), 4.97 (s, 2H, C4-CH2), 6.63 (s,
1H, C3-H), 6.80–7.68 (m, 5H, Ar-H), 8.23 (s, 1H, C5-H), 8.39 (s, 1H,
NH, D2O exchangeable). Anal. Calcd for C17H13ClN4O4S (%): Calcd. C,
50.44; H, 3.24; N, 13.84. Found: C, 50.32; H, 3.16; N, 13.78.
5.1.4.15. 4-Azidomethyl-7-methyl-coumarin-6-sulfonic acid (3-
chloro-phenyl)-amide (5o). Grey solid; yield 61%; m.p. 196 C; IR
(KBr) cm1 1719 (C]O), 2128 (N3), 3395 (NH); 1H NMR (DMSO,
300 MHz, TMS): d 2.68 (s, 3H, C7-CH3), 4.98 (s, 2H, C4-CH2), 6.34 (s,
1H, C3-H), 6.58–7.69 (m, 5H, Ar-H), 8.24 (s, 1H, C5-H), 8.38 (s, 1H,
NH, D2O exchangeable); LC-MS 405 (M þ H). Anal. Calcd for
C17H13ClN4O4S (%): Calcd. C, 50.44; H, 3.24; N, 13.84. Found: C,
50.38; H, 3.20; N, 13.80.
5.1.4.16. 4-Azidomethyl-7-methyl-coumarin-6-sulfonic acid (4-
chloro-phenyl)-amide (5p). Colorless solid; yield 63%; m.p. 140 C;
IR (KBr) cm1 1725 (C]O), 2122 (N3), 3395 (NH); 1H NMR (DMSO,
300 MHz, TMS): d 2.66 (s, 3H, C7-CH3), 4.93 (s, 2H, C4-CH2), 6.62 (s,
1H, C3-H), 7.10–7.65 (m, 5H, Ar-H), 8.22 (s, 1H, C5-H), 8.36 (s, 1H,
NH, D2O exchangeable). Anal. Calcd for C17H13ClN4O4S (%): Calcd. C,
50.44; H, 3.24; N, 13.84. Found: C, 50.39; H, 3.20; N, 13.76.
5.1.4.17. 4-Azidomethyl-7-methyl-coumarin-6-sulfonic acid (2,4-
dichloro-phenyl)-amide (5q). Black solid; yield 67%; m.p. 165 C; IR
(KBr) cm1 1726 (C]O), 2121 (N3), 3429 (NH); 1H NMR (DMSO,
300 MHz, TMS): d 2.68 (s, 3H, C7-CH3), 4.98 (s, 2H, C4-CH2), 6.63 (s,
1H, C3-H), 6.81–7.71 (m, 4H, Ar-H), 8.24 (s, 1H, C5-H), 8.40 (s, 1H,
NH, D2O exchangeable). Anal. Calcd for C17H12Cl2N4O4S (%): Calcd.
C, 46.48; H, 2.75; N, 12.75. Found: C, 46.41; H, 2.71; N, 12.70.
5.1.4.18. 4-Azidomethyl-7-methyl-coumarin-6-sulfonic acid (3,4-
dichloro-phenyl)-amide (5r). Grey solid; yield 62%; m.p. 196 C; IR
(KBr) cm1 1726 (C]O), 2123 (N3), 3374 (NH); 1H NMR (DMSO,
300 MHz, TMS): d 2.68 (s, 3H, C7-CH3), 4.98 (s, 2H, C4-CH2), 6.63 (s,
1H, C3-H), 6.81–7.68 (m, 4H, Ar-H), 8.23 (s, 1H, C5-H), 8.37 (s, 1H,
NH, D2O exchangeable). Anal. Calcd for C17H12Cl2N4O4S (%): Calcd.
C, 46.48; H, 2.75; N, 12.75. Found: C, 46.45; H, 2.69; N, 12.67.
5.1.4.19. 4-Azidomethyl-7-methyl-coumarin-6-sulfonic acid (4-
bromo-phenyl)-amide (5s). Brown solid; yield 58%; m.p. 175 C; IR
(KBr) cm1 1709 (C]O), 2112 (N3), 3354 (NH); 1H NMR (DMSO,
300 MHz, TMS): d 2.65 (s, 3H, C7-CH3), 4.91 (s, 2H, C4-CH2), 6.38 (s,
1H, C3-H), 6.61–8.38 (m, 7H, Ar-H and NH). Anal. Calcd for
C17H13BrN4O4S (%): Calcd. C, 45.45; H, 2.92; N, 12.47. Found: C,
45.37; H, 2.88; N, 12.37.
5.1.4.20. 4-Azidomethyl-7-methyl-coumarin-6-sulfonic acid (3-
chloro-4-methyl-phenyl)-amide (5t). Yellow solid; yield 60%; m.p.
154 C; IR (KBr) cm1 1726 (C]O), 2135 (N3), 3374 (NH); 1H NMR
(DMSO, 300 MHz, TMS): d 2.15 (s, 3H, 4-CH3 of phenyl), 2.68 (s, 3H,
C7-CH3), 4.98 (s, 2H, C4-CH2), 6.34 (s, 1H, C3-H), 6.56–7.75 (m, 4H,
Ar-H), 8.24 (s, 1H, C5-H), 8.39 (s, 1H, NH, D2O exchangeable). Anal.
Calcd for C18H15ClN4O4S (%): Calcd. C, 51.62; H, 3.61; N, 13.38.
Found: C, 51.58; H, 3.55; N, 13.29.
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chloro-5-nitro-phenyl)-amide (5u). Yellow solid; yield 58%; m.p.
153 C; IR (KBr) cm1 1729 (C]O), 2122 (N3), 3429 (NH); 1H NMR
(DMSO, 300MHz, TMS): d 2.68 (s, 3H, C7-CH3), 4.99 (s, 2H, C4-CH2),
6.06 (s, 1H, C3-H), 6.65–7.62 (m, 4H, Ar-H), 8.23 (s, 1H, C5-H), 8.41
(s, 1H, NH, D2O exchangeable). Anal. Calcd for C17H12ClN5O6S
(%): Calcd. C, 45.39; H, 2.69; N, 15.57. Found: C, 45.32; H, 2.61; N,
15.50.
5.1.4.22. 4-Azidomethyl-7-methyl-coumarin-6-sulfonic acid (4-
chloro-2-nitro-phenyl)-amide (5v). Yellow solid; yield 56%; m.p.
189 C; IR (KBr) cm1 1726 (C]O), 2122 (N3), 3430 (NH); 1H NMR
(DMSO, 300MHz, TMS): d 2.68 (s, 3H, C7-CH3), 4.98 (s, 2H, C4-CH2),
6.63 (s, 1H, C3-H), 6.81–7.69 (m, 4H, Ar-H), 7.93 (s, 1H, NH, D2O
exchangeable), 8.23 (s,1H, C5-H). Anal. Calcd for C17H12ClN5O6S (%):
Calcd. C, 45.39; H, 2.69; N, 15.57. Found: C, 45.35; H, 2.64; N, 15.54.
5.1.4.23. 4-Azidomethyl-7-methyl-coumarin-6-sulfonic acid (4-
methyl-2-nitro-phenyl)-amide (5w). Yellow solid; yield 59%; m.p.
179 C; IR (KBr) cm1 1725 (C]O), 2122 (N3), 3347 (NH); 1H NMR
(DMSO, 300 MHz, TMS): d 2.18 (s, 3H, 4-CH3 of phenyl), 2.67 (s, 3H,
C7-CH3), 4.97 (s, 2H, C4-CH2), 6.63 (s, 1H, C3-H), 6.80–7.68 (m, 4H,
Ar-H), 7.74 (s, 1H, NH, D2O exchangeable), 8.23 (s, 1H, C5-H). Anal.
Calcd for C18H15N5O6S (%): Calcd. C, 50.35; H, 3.52; N, 16.31. Found:
C, 50.29; H, 3.41; N, 16.27.
5.1.4.24. 4-Azidomethyl-7-methyl-coumarin-6-sulfonic acid (2-
methyl-4-nitro-phenyl)-amide (5x). Yellow solid; yield 60%; m.p.
110 C; IR (KBr) cm1 1720 (C]O), 2121 (N3), 3360 (NH); 1H NMR
(DMSO, 300 MHz, TMS): d 2.08 (s, 3H, 2-CH3 of phenyl), 2.65 (s, 3H,
C7-CH3), 5.39 (s, 2H, C4-CH2), 6.57 (s, 1H, C3-H), 6.72–8.27 (m, 6H,
Ar-H and NH). Anal. Calcd for C18H15N5O6S (%): Calcd. C, 50.35; H,
3.52; N, 16.31. Found: C, 50.11; H, 3.29; N, 16.12.
5.1.4.25. 4-Azidomethyl-7-methyl-coumarin-6-sulfonic acid naph-
thalen-1-ylamide (5y). Grey solid; yield 64%; m.p. 199 C; IR (KBr)
cm11729 (C]O), 2128 (N3), 3410 (NH); 1H NMR (DMSO, 300 MHz,
TMS): d 2.69 (s, 3H, C7-CH3), 4.98 (s, 2H, C4-CH2), 6.39–8.05 (m, 9H,
Ar-H), 8.24 (s, 1H, C5-H), 8.55 (s, 1H, NH, D2O exchangeable). Anal.
Calcd for C21H16N4O4S (%): Calcd. C, 59.99; H, 3.84; N, 13.33. Found:
C, 59.85; H, 3.78; N, 13.27.
5.2. Anti-bacterial screening
Standard strains were procured from the microbial type culture
collection and Gene Bank (MTCC), Institute of Microbial Tech-
nology, Chandigarh, India. The anti-bacterial activity of the
synthesized compounds 2, 3, 5a-y were performed in vitro against
(i) Gram-positive bacteria: S. faecalis (MTCC 3382), S. aureus (MTCC
3160), B. subtilis (MTCC 297) and (ii) Gram-negative bacteria: P.
aeruginosa (MTCC 1034), K. pneumoniae (MTCC 3384) and E. coli
(MTCC 1089) by broth micro dilution method [29].
The MIC determination of the tested compounds was investi-
gated in comparisonwith Ciproﬂoxacin. Double dilutions of the test
compounds and reference drugs were prepared in Muller-Hinton
agar. 10 mg of each test compounds were dissolved in 1 ml of
dimethyl sulfoxide (DMSO) separately to prepare stock solution.
Further, progressive dilutions with melted Mueller–Hinton agar
were performed to obtain the required concentrations of 500, 250,
125, 62.5, 31.25,16, 8, 4, 2, 1 mg/ml. The Petri dishes were inoculated
with 1–5104 colony forming units (cfu/ml) and incubated at 37 C
for 18 hours. The minimum inhibitory concentration (MIC) was the
lowest concentration of the tested compounds that yield no visible
growth on the plate was recorded in Table 1. To ensure that the
solvent had no effect on the bacterial growth, a control wasperformed with the test medium supplemented with DMSO at the
same dilutions as used in the experiments.
5.3. Anti-fungal screening
The anti-fungal activity was performed against the following
standard fungal strains: C. albicans, A. fumigatus, A. niger, P. chrys-
ogenum, M. fuscus and F. oxysporum.
The MIC determination of the tested compounds was investi-
gated in comparison with Fluconazole by broth micro dilution
method [30]. Double dilutions of the test compounds and reference
drugs were prepared in Sabouraud’s dextrose broth. 10 mg of each
test compounds were dissolved in 1 ml of dimethyl sulfoxide
(DMSO) separately to prepare stock solution. Further progressive
dilutions with Sabouraud’s dextrose broth were performed to
obtain the required concentrations of 500, 250, 125, 62.5, 31.25, 16,
8, 4, 2, 1 mg/ml. The Petri dishes were inoculated with 1–5  104
colony forming units (cfu/ml) and incubated at 25 C for 48–72 h.
The minimum inhibitory concentration (MIC) was the lowest
concentration of the tested compound that yield no visible growth
on the plates. To ensure that the solvent had no effect on the fungal
growth, a control was performed with the test medium supple-
mented with DMSO at the same dilutions as used in the experi-
ments. The results are incorporated in Table 2.
6. Conclusions
We have synthesized a series of coumarin sulfonamides bearing
an azido group. The investigation of antimicrobial screening data
reveals that the synthesized compounds showed signiﬁcant anti-
bacterial activity to both Gram-positive and Gram-negative species.
In many cases these showed equivalent to Ciproﬂoxacin. On the
other hand these compounds showed fungicidal activity which was
higher than Fluconazole. As a result, we can say that these are
better fungicidal when their antimicrobial activity is compared.
Hence, it is concluded that there is ample scope for further study in
developing these as good lead compounds in developing new
antimicrobials.
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